Your browser doesn't support javascript.
loading
Validation of a Harmonized Enzyme-Linked-Lectin-Assay (ELLA-NI) Based Neuraminidase Inhibition Assay Standard Operating Procedure (SOP) for Quantification of N1 Influenza Antibodies and the Use of a Calibrator to Improve the Reproducibility of the ELLA-NI With Reverse Genetics Viral and Recombinant Neuraminidase Antigens: A FLUCOP Collaborative Study.
Bernard, Marie-Clotilde; Waldock, Joanna; Commandeur, Sylvie; Strauß, Lea; Trombetta, Claudia Maria; Marchi, Serena; Zhou, Fan; van de Witte, Serge; van Amsterdam, Peter; Ho, Sammy; Hoschler, Katja; Lugovtsev, Vladimir; Weir, Jerry P; Montomoli, Emanuele; Cox, Rebecca J; Engelhardt, Othmar G; Friel, Damien; Wagner, Ralf; Ollinger, Thierry; Germain, Sophie; Sediri-Schön, Hanna.
Afiliación
  • Bernard MC; Department of Research and Development, Sanofi Pasteur, Marcy L'Etoile, France.
  • Waldock J; Influenza Resource Centre, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.
  • Commandeur S; Department of Research and Development, Sanofi Pasteur, Marcy L'Etoile, France.
  • Strauß L; Section viral vaccines, Virology Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
  • Trombetta CM; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
  • Marchi S; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
  • Zhou F; Influenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
  • van de Witte S; Abbott Healthcare Products B.V., Weesp, Netherlands.
  • van Amsterdam P; Abbott Healthcare Products B.V., Weesp, Netherlands.
  • Ho S; UK Health Security Agency, Colindale, United Kingdom.
  • Hoschler K; UK Health Security Agency, Colindale, United Kingdom.
  • Lugovtsev V; Laboratory of DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
  • Weir JP; Laboratory of DNA Viruses, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States.
  • Montomoli E; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
  • Cox RJ; Influenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
  • Engelhardt OG; Influenza Resource Centre, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.
  • Friel D; GlaxoSmithKline (GSK), Wavre, Belgium.
  • Wagner R; Section viral vaccines, Virology Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
  • Ollinger T; GlaxoSmithKline (GSK), Wavre, Belgium.
  • Germain S; GlaxoSmithKline (GSK), Wavre, Belgium.
  • Sediri-Schön H; Section viral vaccines, Virology Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
Front Immunol ; 13: 909297, 2022.
Article en En | MEDLINE | ID: mdl-35784305
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana Límite: Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana Límite: Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Francia